Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Latest News

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Published

on

USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, May 9, 2024 /PRNewswire/ — USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer Moon Shot” designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

In the case of pelareorep, an intravenously delivered immunotherapy agent developed by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), the case is getting stronger for it to one day become a treatment for multiple cancers, including most prominently pancreatic cancer. Near the end of 2022, the FDA granted pelareorep a Fast Track Designation for the treatment of pancreatic ductal adenocarcinoma (PDAC) after it demonstrated some optimistic results. Now Oncolytics is continuing to move its flagship asset forward, having recently received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRONOX +/- Tecentriq® (from Roche) in pancreatic cancer in a new cohort for its ongoing GOBLET study, following German regulatory and ethics approvals.

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.

Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC,” said Dr. Matt Coffey, President and CEO of Oncolytics. “We believe that working with PanCAN will help to further enrich Oncolytics’ clinical relationships with the pancreatic cancer community. We are also grateful for PanCAN’s Therapeutic Accelerator Award, which is enabling the evaluation of this combination therapy.”

Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep’s potential in addressing pancreatic cancer. So far, Oncolytics has already reported data for pelareorep in combination with gemcitabine and nab-paclitaxel. According to the Oncolytics team, if the mFOLFIRINOX combination shows a compelling efficacy signal, this therapeutic approach could also be advanced to a registration-enabling study, providing two opportunities for pelareorep-based treatment to benefit pancreatic cancer patients. In addition, translational research studies planned for this cohort will help to further elucidate pelareorep’s mechanism of action, including its ability to shape the tumor microenvironment (TME).

Oncolytics has taken a very strategic approach to the development of pelareorep in pancreatic cancer by focusing its clinical studies on combinations with the most widely used treatment regimens,” said Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial. “My experience to date with the GOBLET study, including the positive metastatic PDAC and encouraging anal cancer data reported last year, makes me enthusiastic to initiate enrollment in the mFOLFIRINOX cohort.”

Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs) in the blood, an effect that was observed in earlier pancreatic cancer studies. According to the company, they will be initiating enrollment into the mFOLFIRINOX/pelareorep study cohort in Q2 2024.

In the case of Candel Therapeutics, Inc. (NASDAQ: CADL), another potential treatment for pancreatic cancer was given a nod by the FDA in the form of an Orphan Drug Designation given to Candel’s most advanced multimodal biological candidate, CAN-2409. The news of the designation came weeks after Candel reported updated overall survival data from its ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable PDAC.

“We recently reported data from the phase 2 randomized clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. “We are pleased that the FDA has now granted Candel with both Orphan Drug and Fast Track Designation to this program, as we seek to reshape the treatment paradigm in pancreatic cancer.”

Pharma giant AstraZeneca PLC (NASDAQ: AZN) recently saw its revenue spike in Q1 2024, bolstered by sales of its cancer medicines, according to Bloomberg. Over the last few weeks, AstraZeneca has been making more progress across the oncology scene, including the release of topline findings from its Phase III DESTINY-Breast06 study, showing significant progression-free survival benefits in certain patients with metastatic breast cancer with its antibody-drug conjugate Enerhertu with partners Daiichi Sankyo.

As well, AstraZeneca also reported results for its CALQUENCE combination regimen, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival improvement in 1st-line mantle cell lymphoma from its ECHO Phase III trial.

“These impactful results in mantle cell lymphoma show that bringing CALQUENCE to the first-line setting significantly delays disease progression and, for the first time, shows potential to extend survival,” said Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca. “The improvement in progression-free survival together with the differentiated safety profile of CALQUENCE are both important as we strive to transform outcomes earlier in the course of disease treatment.”

In combination with its Enhanze drug-delivery technology, Halozyme Therapeutics, Inc. (NASDAQ: HALO) was recently linked to the acceptance of an approval-seeking FDA application involving a subcutaneous formulation of Bristol-Myers Squibb’s blockbuster cancer drug Opdivo. As per the announcement, the application covers Opdivo co-formulated with Halozyme’s Enhanze drug-delivery technology across all previously approved adult, solid-tumor Opdivo indications as monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy or in combination with chemotherapy or cabozantinib.

Back in January, Halozyme also saw its other co-collaborator, Roche, receive European Commission approval of Tecentriq® SC with Enhanze, representing the EU’s first subcutaneous PD-(L)1 cancer immunotherapy for multiple cancer types.

“As the first subcutaneous PD-(L)1 cancer immunotherapy in Europe, Tecentriq SC can provide a new treatment option that can enhance the treatment experience for patients and caregivers while freeing up resources in constrained healthcare systems,” said Dr. Helen Torley, President and CEO of Halozyme.

Back in February, Janux Therapeutics, Inc. (NASDAQ: JANX) announced encouraging safety and efficacy data in ongoing dose escalation trials for PSMAxCD3-TRACTr JANX007 in metastatic castration-resistant prostate cancer (mCRPC) and EGFRxCD3-TRACTr JANX008 in late-stage solid tumors.

“The clinical data provide compelling proof-of-concept for the TRACTr platform in a setting where many other approaches have failed due to material safety issues or lack of efficacy,” said David Campbell, Ph.D., President and CEO, Janux Therapeutics. “Our TRACTr platform provides an entry point to multiple, large solid tumor indications that are intractable with conventional TCE approaches. We look forward to continuing to advance these clinical trials and expanding to additional TCE targets, as we look to fulfill our mission to meaningfully address the unmet medical needs for cancer patients, especially those with late-stage disease.”

The market’s immediate reaction was quite positive upon these results, but by mid-April Janux began working with an adviser after drawing interest in a potential takeover. According to Bloomberg, Janux is likely to draw interest from bigger drugmakers who are looking to acquire new medicines to replenish their portfolios or expand into cancer treatments. Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Article Source: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

USA NEWS GROUP
[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/biotech-innovations-surge-as-global-cancer-diagnosis-rates-continue-to-climb-302141329.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Unlock an Exclusive Olympic Experience: Celebrating Live4Well’s Sold-Out Genesis NFT

Published

on

HONG KONG, May 25, 2024 /PRNewswire/ — The buzz surrounding Live4Well’s successful Genesis NFT membership launch on May 23 has captivated both traditional and web3 communities. Combining the power of AI technology and decentralized physical infrastructure (DePin) concept, Live4Well has infused new life into the NFT market. The overwhelming response to their first NFT sales, showcases the project’s immense potential. Renowned web3 community leaders from Azuki, Bored Ape, Pudgy Penguins, WELL3, etc have joined forces with Live4Well, propelling the Genesis NFT membership collection to its resounding success.

Live4Well aims to transform the wellness industry by creating a reward-based infrastructure that connects global fitness data, enhances their AI database, and drives the development of sports and wellness. Backed by a multi-billion family office, which recently invested $20 million in Live4Well, the project has gained support in both web3 and traditional spaces. The team believes that every drop of sweat and effort toward better health should be rewarded, fostering motivation and integrating exercise into daily lives for enhanced well-being.

Live4Well’s announcement of an Olympic-themed raffle for Genesis NFT holders reflects their commitment to connecting wellness between Web2 and Web3 platforms. This testament to Live4Well’s demand and innovative vision solidifies their position as a promising leader in the industry. Their integration of the Olympic signifies their determination to inspire a global audience, leveraging blockchain technology to create an immersive ecosystem that revolutionizes how individuals engage with fitness on a daily basis for better health. Live4Well’s dedication to bridging the gap between traditional practices and the digital landscape sets them apart as pioneers in promoting well-being on a global scale.

What is Genesis NFT membership?

The Genesis NFT unlocks a multitude of benefits for holders, including the opportunity to cash out their sportive income and access a range of exclusive physical products and services. In addition to future airdrops and angel round whitelist privileges, Genesis holders will receive VIP tailor-made product packs from an innovative German sportswear company, elevating their exercise performance to new heights. With over 400 million sweat points farmed by their users, they are eager to redeem through the Genesis NFT membership. These enticing incentives explain why there was a widespread eagerness to participate in this thrilling event.

Unlike typical projects that raise funds before launching products or services, Live4Well has already released its AI-powered app, amassing over 250,000 users as a community base actively engaging in daily exercise. This early success has fostered a promising community within the wellness industry, as users trust Live4Well’s roadmap and collaborative ventures. The growing traction from both ordinary individuals and web3 enthusiasts has intensified the demand for redeeming and cashing out sweat points, the project’s exercise-based rewards. Obtaining the Genesis NFT membership is now seen as an essential step for accessing the highest tier of benefits and cashing out sportive income.

(PRNewsfoto/Live4Well)

What’s next for Live4Well?

Following the Genesis sales, Live4Well’s team will shift their focus to the upcoming token generation event (TGE) and a series of farming events. They also have exciting plans for partnerships and other collaborations in the global wellness and fitness industries. If you missed the initial launch, be sure to stay updated on Live4Well’s journey and join this extraordinary revolution.

(PRNewsfoto/Live4Well)

Photo – https://mma.prnewswire.com/media/2421983/image.jpg

Photo – https://mma.prnewswire.com/media/2421640/Live4Well.jpg

Logo – https://mma.prnewswire.com/media/2421641/4725441/Live4Well.jpg

 

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/unlock-an-exclusive-olympic-experience-celebrating-live4wells-sold-out-genesis-nft-302155644.html

Continue Reading

Latest News

CGTN: Eyeing Chinese modernization, China doubles efforts to further deepen reform on all fronts

Published

on

BEIJING, May 25, 2024 /PRNewswire/ — Built after China’s reform and opening up, Rizhao Port in east China’s Shandong Province is a vital global hub for the transshipment of energy and bulk raw materials.

Through recent technological innovation, the port has been upgraded into a modern port, serving as a key node for the New Eurasian Land Bridge and an important hub for the Belt and Road Initiative.

Rizhao Port, together with Qingdao Port, Yantai Port and Bohai Bay Port, formed Shandong Port Group Co., Ltd. five years ago. Last year, the total cargo throughput of the four ports exceeded 1.7 billion tonnes, ranking first in the world.

As part of his first leg of an inspection tour in Shandong Province from Wednesday to Friday, Xi Jinping, general secretary of the Communist Party of China (CPC) Central Committee, visited the port, recognizing its achievements and urging the province to build a high-level platform for major international exchanges and cooperation.

“Reform is the driving force for development,” Xi emphasized on Thursday while chairing a symposium in Shandong’s capital of Jinan, attended by representatives from businesses and academia.

To deepen reform further on all fronts, efforts should be focused on the overarching goals of improving and developing the socialist system with Chinese characteristics and modernizing China’s governance system and capacity, he stressed.

Deepening reform centered on Chinese modernization

Xi’s trip to Shandong is the first local inspection he has made since the CPC Central Committee Political Bureau held a meeting on April 30, which decided that the third plenary session of the 20th CPC Central Committee will be held in Beijing in July, and the session will primarily examine issues related to further comprehensively deepening reform and advancing Chinese modernization.

Over the years, China’s reform of the economic system has been continuously improved, and the reform of its political and cultural systems has been steadily advanced and innovated.

Meanwhile, the reform of the ecological civilization system has been accelerated, and the reform of national defense and the military has achieved historic breakthroughs.

Comprehensively deepening reform has placed the construction of the national governance system and governance capabilities in a more prominent position. China has convened about 40 meetings of the Central Leading Group for Comprehensively Deepening Reform and 30 meetings of the Central Commission for Comprehensively Deepening Reform to improve the top-level design of reform.

From implementing the Foreign Investment Law and building pilot free trade zones to hosting a slew of major expos and accelerating the construction of Hainan Free Trade Port, China unswervingly deepens reforms and expands high-level opening up, injecting positive energy into global development and bringing tangible benefits to people worldwide.

At Thursday’s symposium, Xi said China should take resolute steps to remove the ideological and institutional barriers hindering the advancement of Chinese modernization and double down on its efforts to resolve deep-seated institutional challenges and structural issues.

Economic system reform should start with meeting realistic needs and tackling the most urgent matters, and it should advance theoretical and institutional innovation in the process of solving practical problems, he added.

A better life for the people

Xi has been stressing that reform should focus on what the people care about and expect the most. The aim, he has said, is to give the people a stronger sense of fulfillment.

Focusing on resolving the most practical problems that are of the greatest and most direct concerns to the people, China has continued to advance major reforms and system construction in the field of people’s livelihoods to allow the results of reform to benefit all people equally and promote their comprehensive development.

The Civil Code, anticipated for decades, finally came to life and was adopted in 2020, highlighting the respect and protection of individual freedom, dignity, interests and rights.

Since the 18th CPC National Congress, the country has built a total of more than 59 million units of various types of affordable and shantytown-renovated housing, helping settle over 140 million people into new homes.

“The Chinese people’s aspiration for a better life is the goal we have been striving for, and the ultimate purpose of advancing reform and promoting development is to improve the livelihood of the people,” Xi said.

Stressing the need to plan and advance reform based on the overall, fundamental and long-term interests of the people, Xi urged efforts to identify the key areas of reform and achieve breakthroughs based on the pressing concerns and aspirations of the general public, including employment, income growth, education, healthcare, housing, government services, childcare, elderly care, personal safety and property security.

https://news.cgtn.com/news/2024-05-24/Eyeing-Chinese-modernization-China-doubles-efforts-to-deepen-reform-1tRFe7yRTUY/p.html

View original content:https://www.prnewswire.co.uk/news-releases/cgtn-eyeing-chinese-modernization-china-doubles-efforts-to-further-deepen-reform-on-all-fronts-302155632.html

Continue Reading

Latest News

PagBank records its highest recurring net income in Q124, reaching 522 million BRL – an increase of +33% in the annual comparison

Published

on

TPV reached 112 billion BRL (+27% YoY), more than twice the industry’s growth and 31 billion BRL in deposits, reinforcing the balance sheet for expansion of receivables anticipation and credit concession.

SÃO PAULO, May 24, 2024 /PRNewswire/ — PagBank (NYSE: PAGS), a complete digital bank in financial services and payments solution and one of the largest digital banks in Brazil, announces its results for the first quarter of 2024 (Q124). The main highlights of the period include a record recurring net profit  of 522 million BRL (+33% YoY), while the net accounting profit reached 483 million BRL (+31 YoY%).

Alexandre Magnani, CEO of PagBank, points out the continuity of the good results presented in the last quarters, highlighting the expressive gain of market share in payments (acquirings), balancing growth with profitability, while the Company establishes itself among the largest financial institutions in Brazil in number of clients:

“We are more than 31 million customers and our execution has been consistent. We have consolidated our value proposition for micro, small, and medium-sized enterprises, facilitating the financial life of individuals and businesses. At the same time, we have captured opportunities for client-consumers who do not have a relationship with payment machines through payroll loans, our broad investment platform, and the offer of a complete bank,” says the CEO of PagBank.

In acquirings, the TPV registered was 112 billion BRL (+27% YoY), growing in all segments (MSMBs and Large Companies, E-commerce, and Cross-border businesses1). In digital banking, PagBank reached 66 billion BRL in Cash-In (+48% YoY), a metric that represents the financial volume received from other financial institutions in PagBank accounts, excluding acquisition, especially Pix, business account products, and salary portability.

The substantial volumes of TPV and Cash-in led deposits to record numbers of nearly 31 billion BRL (+64% YoY and +11%QoQ) despite the less favorable seasonality of the period, given that in the first months of the year, customers have more significant disbursements to honor the payment of taxes, such as IPTU and IPVA, and school yearly supplies, among other expenses.“We stand out for offering instant settlement for our customers and carrying out easy operations via Pix, leveraging our TPV and Cash-In volume in PagBank accounts. This, added to the fact that we have a banking license since 2019, means that we have the agility of a fintech and low funding costs like a traditional bank,” says Magnani. 

According to Artur Schunck, CFO of PagBank, operational growth does not harm the Company’s capital allocation. On the contrary, the acceleration of revenue growth and discipline in costs and expenses were the main levers of the record result. “The financial margins of the consolidated business were high. Our profit grew more than 30% compared to the Q1 2023, even with additional disbursements linked to the new cycle of growth and diversification of the operation, including geographical expansion and marketing actions in the period”, says Schunck.

The credit portfolio resumed growth and reached 2.7 billion (+8% QoQ) at the end of March, focusing on low-risk products such as consigned credit, the anticipation of the year withdrawal of FGTS (Severance Pay Fund), and credit cards with a limit attached to PagBank’s CDBs (a type of fixed-income investment). Schunck believes that despite short-term macroeconomic uncertainties regarding interest and inflation behavior, the worst is in the past, and he is confident in the credit strategy:

“We crossed the pandemic, the significant high-interest rate period, and one of the worst credit cycles in Brazil and still we have built a robust balance sheet and diversified our credit portfolio in terms of customers, products, and risks. Now, we are opening up opportunities to accelerate the concession and gradually expand the offer of credit products from the next few months,” says the CFO of PagBank. 

Other Highlights

Net revenue in the quarter was 4.3 billion BRL (+15% YoY), driven by the strong growth of the acquirings, led by MSMBs (micro, small and medium-sized businesses) and the advance in large accounts, with emphasis on online, cross-border, and automation, as well as the growth of higher margins in financial services. The number of clients reached 31.4 million, reinforcing PagBank’s position as one of the largest digital banks in the country.

In the period, PagBank was recognized as the best bank in Brazil and awarded the RA1000 seal of quality in service, both granted by the Reclame Aqui ranking and as one of the 50 most valuable brands in the country, according to a survey conducted by Kantar BrandZ.

Among the launches of the quarter, main highlights were PagBankPartnerships, a relationship and integration program with software companies and commercial automation; Seguro Empresarial (Business Insurance) offering coverage against fires, electrical damage, theft, burglary, and natural disasters, among others; and Tap to Pay Online, a new and exclusive technology in Latin America that allows the customer to run online transactions by bringing credit or debit card closer to the mobile phone on e-commerce platforms. In addition, PagBank has started to offer 1% cashback on all purchases made with the digital bank credit card and new investment options, such as the CBD, with a 130% CDI rate-variation yield.

“This current moment reminds us very much of our phase between 2018 and 2019, in which we grew in a fast and profitable way, and launched several products. We are very optimistic about the coming months and years of the Company”, says the CEO of PagBank. 

Rio Grande do Sul

PagBank has closely monitored the potential impacts of the ongoing climate tragedy in the state of Rio Grande do Sul and the developments in its operations. The Company’s TPV exposure in the state is similar to the state’s share in national GDP – around 5%. The Company says t is early to share some numbers since consumption in the affected regions have decreased due to the temporary closure of the business, while moving people to neighboring cities and states can increase consumption in unaffected areas.

“At this time, our focus is on supporting flood victims, especially our professionals working in the state of Rio Grande do Sul, through donations from PagBank and its professionals, in cash and goods, as well as offering special support to our affected customer,” says Magnani. 

Check out the financial results of PagBank in Q124 here.

About PagBank
PagBank promotes innovative solutions in financial services and means of payment, automating the purchase, sale, and transfer process to leverage individuals’ and enterprises’ businesses simply and securely. A company of the UOL Group – leader of the Brazilian Internet – PagBank acts as an issuer and acquirer, offering digital accounts and providing complete solutions for online and face-to-face payments (by mobile devices and POS devices). 

PagBank also has a wide variety of means of payment, such as credit and prepaid cards, bank transfers, payments by billet, and balance in the account, among others. PagBank (PagSeguro Internet Payment Institution S.A) is regulated by the Central Bank of Brazil as an electronic money-issuing payment institution, issuer of post-paid instruments and acquirer, having partnerships with the leading credit card issuers. Its parent company, PagSeguro Digital, is listed in the U.S. (NYSE: PAGS) and regulated by the Securities and Exchange Commission (SEC). The distribution of investment funds is carried out by BancoSeguro S.A., authorized by the Central Bank of Brazil, the Securities and Exchange Commission, and affiliated with ANBIMA. 

Visit the PagBank Press Room

1 GCECs: The Brazilian acronym for large companies (annual revenues above 12 million BRL), e-commerce and cross-border businesses.

Photo – https://mma.prnewswire.com/media/2421050/PagBank.jpg

Logo – https://mma.prnewswire.com/media/2348972/logo_pagbank_01__1_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/pagbank-records-its-highest-recurring-net-income-in-q124-reaching-522-million-brl–an-increase-of-33-in-the-annual-comparison-302155508.html

Continue Reading

Trending